Specificity of the TGF-β assaya
| Expt. . | Anti-CD2 . | Medium (pg/ml) . | Anti-TGF-β (pg/ml) . | mIgG1 . |
|---|---|---|---|---|
| 1 | − | 229 | <5 | 279 |
| + | 593 | <5 | 284 | |
| 2 | − | 210 | <5 | 360 |
| + | 445 | <5 | 288 | |
| 3 | − | 722 | <5 | 764 |
| + | 1365 | <5 | 1359 | |
| 4 | − | 3807 | <5 | 2121 |
| + | >8000 | 96 | 3886 |
| Expt. . | Anti-CD2 . | Medium (pg/ml) . | Anti-TGF-β (pg/ml) . | mIgG1 . |
|---|---|---|---|---|
| 1 | − | 229 | <5 | 279 |
| + | 593 | <5 | 284 | |
| 2 | − | 210 | <5 | 360 |
| + | 445 | <5 | 288 | |
| 3 | − | 722 | <5 | 764 |
| + | 1365 | <5 | 1359 | |
| 4 | − | 3807 | <5 | 2121 |
| + | >8000 | 96 | 3886 |
PBL (1 × 105 were incubated with or without anti-CD2 for 48 h, and the supernatants were harvested. Anti-TGF-β (10 μg/ml) or an equivalent amount of control mouse IgG1 was added, and the supernatant was examined for total TGF-β activity using mink cells (MLEC) with a luciferase construct.